ArticleBlood transfusion = Trasfusione del sangue
Molecular mechanism of a novel Aweak subtype in Chinese pedigrees: identification and analysis of a large genomic deletion in the promoter upstream distal region of the ABO gene.
Article in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate ABO typing is essential for transfusion safety, yet weak A/B subgroups continue to present diagnostic challenges. Although most weakened ABO antigen expressions are linked to missense mutations or small indels within coding regions, the contribution of non-coding regulatory variants -especially large structural alterations-remains insufficiently characterized. Standard genotyping methods, including Sanger sequencing and targeted next-generation sequencing, often fail to detect large upstream deletions, leaving some serological-genotypic discrepancies unresolved in donors and patients. Such gaps hinder accurate transfusion risk assessment. To clarify these mechanisms, this study performed detailed ABO blood typing in a donor with an A subgroup and his family and explored the molecular basis for weakened A antigen expression. MATERIALS AND
methodsABO phenotypes of the proband and his parents, spouse, two daughters, and son were determined using serological testing. Full-length ABO gene sequencing was then performed using third-generation single-molecule sequencing.
resultsThe proband, his father, and his son displayed the Aweak phenotype. All three carried a heterozygous 12,309-bp deletion located upstream of the ABO gene promoter, along with a normal ABOA1.02 allele. The remaining family members carried genotypes ABOO.01.01/ABOO.01.01 (mother), ABOB.01/ABOO.01.02 (wife), ABOB.01/ABOO.01.01 (daughter 1), and ABOO.01.01/ABOO.01.02 (daughter 2). No variants were detected in coding regions, introns, or splice sites. Pedigree analysis confirmed that the proband inherited the ABOA1.02 allele with the 12.3-kb deletion from his father and passed it to his son. DISCUSSION: This study identifies, for the first time, a large 12.3-kb upstream deletion of the ABO promoter responsible for weakened erythrocyte A antigen expression. The finding expands current understanding of regulatory mechanisms underlying weak ABO phenotypes and highlights the value of advanced sequencing for transfusion safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.